Journal of Clinical and Molecular Endocrinology

Ketotifen and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus

Objective: Mast cells found to be an important contributor to inflammation, obesity, diabetes and atherosclerosis. We evaluate the ability of ketotifen to reduce cardiovascular risk in patient with type 2 diabetes millets (T2DM).

Method: In a randomized controlled study we recruited forty eight patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. They were classified in to three groups. Group 1: received glimepiride (GL) 3 mg/day alone; group 2: received GL 3 mg/day +ketotifen 1 mg once daily; group 3: received GL 3 mg/day +ketotifen 1 mg twice daily. Fasting blood samples were obtained before and 12 weeks after treatment for biochemical analysis of IL-6 and lipid profile with subsequent calculation of Castelli index 1 and atherogenic coefficient. Body mass index was also calculated for all patients. Data were analyzed by paired student's t-test and one way analysis of variance, p<0.05 was considered statistically significant.

Results: The obtained data suggested that ketotifen in its twice daily dose significantly improves lipid profile and decreases IL-6 level, castelli index 1 and atherogenic coefficient.

Conclusions: Mast cell stabilization with ketotifen can decrease the risk of diabetes associated cardiovascular complications

Author(s):

Sahar M El-Haggar, Wael F Farrag and Fedaa A Kotkata

Abstract | Full-Text | PDF

Share this